This post is a good overview of near-term prospects for human biological enhancement, arguing that selection is more tractable than editing, and further that iterated selection has the potential to be exceptionally powerful. The biology is largely accurate as of the time of writing, although the claim “we can now do iterated meiosis” was premature. Since 2024 I’ve been working on refining my meiosis induction to improve epigenetics and also allow for iterated meiosis. As of early 2026, I’ve made significant progress but this still isn’t ready for use in humans. Sergiy has also made advancements in SuperSOX to allow more efficient reprogramming and epigenetic control.
I think this area of research is important for human flourishing in general, and may potentially help with the AI alignment problem depending on timelines (I know that these days many people’s central estimates are short, but there’s definitely high variance).
Followup work includes biological research (like what we’re doing at Ovelle Bio and what Sergiy is doing at Soxogen) and additional theoretical modeling of genetic optimization.
This post is a good overview of near-term prospects for human biological enhancement, arguing that selection is more tractable than editing, and further that iterated selection has the potential to be exceptionally powerful. The biology is largely accurate as of the time of writing, although the claim “we can now do iterated meiosis” was premature. Since 2024 I’ve been working on refining my meiosis induction to improve epigenetics and also allow for iterated meiosis. As of early 2026, I’ve made significant progress but this still isn’t ready for use in humans. Sergiy has also made advancements in SuperSOX to allow more efficient reprogramming and epigenetic control.
I think this area of research is important for human flourishing in general, and may potentially help with the AI alignment problem depending on timelines (I know that these days many people’s central estimates are short, but there’s definitely high variance).
Followup work includes biological research (like what we’re doing at Ovelle Bio and what Sergiy is doing at Soxogen) and additional theoretical modeling of genetic optimization.